Call for Abstract
Scientific Program
19th International Conference on Alzheimer's disease and Dementia, will be organized around the theme “Rethinking Memory: Future Directions in Alzheimer's Diagnosis, Treatment, and Care”
Alzheimers Disease - 2025 is comprised of 15 tracks and 0 sessions designed to offer comprehensive sessions that address current issues in Alzheimers Disease - 2025.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Early detection of Alzheimer’s disease remains a critical challenge. This session will explore the latest advancements in diagnostic techniques, including the development of novel biomarkers such as amyloid-beta, tau proteins, and neurofilament light chains in blood and cerebrospinal fluid. Emerging neuroimaging technologies, including PET and MRI scans, will also be discussed as tools for detecting Alzheimer’s disease at preclinical stages. By improving early diagnosis, this track will highlight how timely interventions could be deployed before significant neurodegeneration occurs.
Neuroinflammation has increasingly been recognized as a major factor in Alzheimer’s disease progression. This session will explore how immune system dysfunction, particularly the role of microglia and astrocytes, contributes to neuroinflammation and the pathogenesis of dementia. It will examine how targeting neuroinflammation offers a potential therapeutic pathway for slowing or halting disease progression, with a focus on new anti-inflammatory therapies under development.
Understanding the genetic landscape of Alzheimer’s disease is essential for identifying at-risk populations. This track will delve into genetic risk factors, including the APOE4 allele and newly discovered genetic mutations linked to early-onset and late-onset Alzheimer’s. The session will also explore epigenetic mechanisms—how environmental factors and lifestyle choices can influence gene expression without altering the underlying DNA, offering insights into potential preventive strategies.
The pathological accumulation of amyloid-beta plaques and tau tangles remains a hallmark of Alzheimer’s disease. This session will explore current therapies targeting amyloid and tau, as well as novel strategies in development. The discussion will cover FDA-approved drugs, such as anti-amyloid monoclonal antibodies, and new clinical trial results from drugs aiming to halt or reverse tau pathology. By addressing these core pathologies, this track will focus on how therapeutic interventions may modify disease progression.
This track will focus on cognitive rehabilitation strategies aimed at maintaining and improving cognitive function in individuals diagnosed with Alzheimer’s disease. Techniques such as cognitive stimulation therapy, computerized cognitive training, and brain plasticity-enhancing approaches will be explored. Neuroplasticity, the brain's ability to reorganize and form new neural connections, remains a promising area for cognitive improvement, even in the face of neurodegeneration.
Lifestyle factors play a crucial role in mitigating the risk of Alzheimer’s disease. This session will highlight evidence-based research on how factors such as a healthy diet, physical exercise, cognitive stimulation, and social engagement can contribute to reducing the risk of Alzheimer’s and other dementias. The role of the Mediterranean diet, cognitive reserve theory, and how physical activity can impact neurogenesis will also be discussed as potential preventive measures.
The gut-brain axis, which links gut health to brain function, is an emerging area of research in Alzheimer’s disease. This track will investigate the growing evidence connecting the gut microbiome to neuroinflammation and neurodegenerative processes in Alzheimer’s. The session will explore how manipulating the gut microbiome through diet, probiotics, and prebiotics may offer novel approaches for mitigating Alzheimer’s disease progression.
One of the major challenges in Alzheimer’s treatment is the delivery of therapeutic agents across the blood-brain barrier (BBB). This track will explore cutting-edge drug delivery systems designed to overcome this barrier, such as nanoparticle-based systems, liposomal carriers, and other targeted delivery technologies. Discussions will include how these innovations can improve the efficacy of drugs targeting Alzheimer’s pathology.
As understanding of Alzheimer’s disease grows, the need for personalized medicine has become apparent. This session will explore how individualized treatment approaches, informed by genetic profiles, biomarker data, and patient-specific factors, can improve outcomes. Personalized interventions such as pharmacogenomics and tailored lifestyle recommendations will be examined, emphasizing a more patient-centric approach to treatment.
Medications alone are often insufficient for managing Alzheimer’s disease, especially in the later stages. This track will focus on non-pharmacological interventions that can improve the quality of life for patients and caregivers. Therapeutic approaches such as music therapy, art therapy, mindfulness-based interventions, and cognitive-behavioral strategies will be explored as complementary treatments to enhance cognitive function and emotional well-being.
Artificial intelligence (AI) and machine learning (ML) are transforming the diagnosis, monitoring, and treatment of Alzheimer’s disease. This session will highlight how AI and ML technologies are being used to analyze large datasets, improve diagnostic accuracy, predict disease progression, and design personalized treatment plans. The potential of robotics in providing assistive care to Alzheimer’s patients will also be explored.
Caregivers of Alzheimer’s patients often experience significant emotional, physical, and financial burdens. This track will focus on the challenges faced by caregivers, discussing innovative support systems, coping strategies, and technological solutions designed to alleviate caregiver stress. Topics will include respite care, telehealth solutions, and counseling services, aiming to enhance the quality of life for both patients and caregivers.
Research has shown that women are disproportionately affected by Alzheimer’s disease, both in terms of prevalence and severity. This session will explore the biological, hormonal, and lifestyle factors that contribute to these sex differences. It will also discuss gender-specific diagnostic and therapeutic approaches to better address Alzheimer’s in both men and women.
This track will address the unique challenges faced by low- and middle-income countries in diagnosing, treating, and caring for Alzheimer’s patients. Discussions will include barriers to access, healthcare infrastructure challenges, and culturally tailored interventions. The session will also examine global initiatives aimed at reducing disparities in Alzheimer’s care and research.
This track will discuss the latest developments in clinical trial designs aimed at speeding up the discovery of effective Alzheimer’s treatments. Topics will include adaptive trial designs, virtual trials, and patient-centric approaches that ensure more rapid and inclusive recruitment, better data collection, and faster decision-making in drug development.